Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Aug;74(4):525–532. doi: 10.1038/bjc.1996.396

Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice.

A J Versluis 1, P J van Geel 1, H Oppelaar 1, T J van Berkel 1, M K Bijsterbosch 1
PMCID: PMC2074664  PMID: 8761365

Abstract

Selective delivery of cytotoxic anti-neoplastic drugs can diminish the severe side-effects associated with these drugs. Many malignant tumours express high levels of low-density lipoprotein (LDL) receptors on their membranes. Therefore, LDL may be used as a carrier to obtain selective delivery of anti-neoplastic drugs to tumours. The present study was performed to investigate the feasibility of the murine B16 tumour/mouse model for the evaluation of LDL-mediated tumour therapy. LDL binds with high affinity to LDL receptors on cultured B16 cells (Kd, 5.9 +/- 2.3 micrograms ml-1; Bmax 206 +/- 23 ng LDL mg-1 cell protein). After binding and internalisation, LDL was very efficiently degraded: 724 +/- 19 ng LDL mg-1 cell protein h-1. Chloroquine and ammonium chloride completely inhibited the degradation of LDL by the B16 cells, indicating involvement of lysosomes. LDL receptors were down-regulated by 70% after preincubation of B16 cells with 300 micrograms ml-1 LDL, indicating that their expression is regulated by intracellular cholesterol. To evaluate the uptake of LDL by the B16 tumour in vivo, tissue distribution studies were performed in C57/B1 mice inoculated with B16 tumours. For these experiments, LDL was radiolabelled with tyramine cellobiose, a non-degradable label, which is retained in cells after uptake. At 24 h after injection of LDL, the liver, adrenals and the spleen were found to be the major organs involved in LDL uptake, with tissue-serum (T/S) ratios of 0.82 +/- 0.08, 1.17 +/- 0.20 and 0.69 +/- 0.08 respectively. Of all the other tissues, the tumour showed the highest uptake of LDL (T/S ratio of 0.40 +/- 0.07). A large part of the LDL uptake was receptor mediated, as the uptake of methylated LDL was much lower. Although the LDL uptake by the liver, spleen and adrenals is higher than that by the tumour, the LDL receptor-mediated uptake by these organs may be selectively down-regulated by methods that do not affect the expression of LDL receptors on tumour cells. It is concluded that the B16 tumour-bearing mouse constitutes a good model to evaluate the effectiveness of LDL-mediated delivery of cytotoxic (pro)drugs to tumours in vivo.

Full text

PDF
525

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelin B., Raviola C. A., Innerarity T. L., Mahley R. W. Regulation of hepatic lipoprotein receptors in the dog. Rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. J Clin Invest. 1983 Apr;71(4):816–831. doi: 10.1172/JCI110835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bilheimer D. W., Eisenberg S., Levy R. I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. doi: 10.1016/0005-2760(72)90034-3. [DOI] [PubMed] [Google Scholar]
  3. Brown M. S., Goldstein J. L. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell. 1975 Nov;6(3):307–316. doi: 10.1016/0092-8674(75)90182-8. [DOI] [PubMed] [Google Scholar]
  4. Counsell R. E., Pohland R. C. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J Med Chem. 1982 Oct;25(10):1115–1120. doi: 10.1021/jm00352a001. [DOI] [PubMed] [Google Scholar]
  5. Dietschy J. M., Turley S. D., Spady D. K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993 Oct;34(10):1637–1659. [PubMed] [Google Scholar]
  6. Fan D., Bucana C. D., O'Brian C. A., Zwelling L. A., Seid C., Fidler I. J. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res. 1990 Jun 15;50(12):3619–3626. [PubMed] [Google Scholar]
  7. Firestone R. A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem. 1994 Mar-Apr;5(2):105–113. doi: 10.1021/bc00026a002. [DOI] [PubMed] [Google Scholar]
  8. Firestone R. A., Pisano J. M., Falck J. R., McPhaul M. M., Krieger M. Selective delivery of cytotoxic compounds to cells by the LDL pathway. J Med Chem. 1984 Aug;27(8):1037–1043. doi: 10.1021/jm00374a017. [DOI] [PubMed] [Google Scholar]
  9. Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930. doi: 10.1146/annurev.bi.46.070177.004341. [DOI] [PubMed] [Google Scholar]
  10. Habeeb A. F. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem. 1966 Mar;14(3):328–336. doi: 10.1016/0003-2697(66)90275-2. [DOI] [PubMed] [Google Scholar]
  11. Havekes L. M., Schouten D., de Wit E. C., Cohen L. H., Griffioen M., van Hinsbergh V. W., Princen H. M. Stimulation of the LDL receptor activity in the human hepatoma cell line Hep G2 by high-density serum fractions. Biochim Biophys Acta. 1986 Feb 12;875(2):236–246. doi: 10.1016/0005-2760(86)90173-6. [DOI] [PubMed] [Google Scholar]
  12. Hay R. V., Fleming R. M., Ryan J. W., Williams K. A., Stark V. J., Lathrop K. A., Harper P. V. Nuclear imaging analysis of human low-density lipoprotein biodistribution in rabbits and monkeys. J Nucl Med. 1991 Jun;32(6):1239–1245. [PubMed] [Google Scholar]
  13. Hynds S. A., Welsh J., Stewart J. M., Jack A., Soukop M., McArdle C. S., Calman K. C., Packard C. J., Shepherd J. Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim Biophys Acta. 1984 Oct 4;795(3):589–595. doi: 10.1016/0005-2760(84)90189-9. [DOI] [PubMed] [Google Scholar]
  14. Isaacsohn J. L., Lees A. M., Lees R. S., Strauss H. W., Barlai-Kovach M., Moore T. J. Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism. 1986 Apr;35(4):364–366. doi: 10.1016/0026-0495(86)90156-3. [DOI] [PubMed] [Google Scholar]
  15. Kamps J. A., Kuiper J., Kruijt J. K., van Berkel T. J. Complete down-regulation of low-density lipoprotein receptor activity in human liver parenchymal cells by beta-very-low-density lipoprotein. FEBS Lett. 1991 Aug 5;287(1-2):34–38. doi: 10.1016/0014-5793(91)80010-z. [DOI] [PubMed] [Google Scholar]
  16. Kleinherenbrink-Stins M. F., van der Boom J., Bakkeren H. F., Roholl P. J., Brouwer A., van Berkel T. J., Knook D. L. Light- and immunoelectron microscopic visualization of in vivo endocytosis of low density lipoprotein by hepatocytes and Kupffer cells in rat liver. Lab Invest. 1990 Jul;63(1):73–86. [PubMed] [Google Scholar]
  17. Knott T. J., Pease R. J., Powell L. M., Wallis S. C., Rall S. C., Jr, Innerarity T. L., Blackhart B., Taylor W. H., Marcel Y., Milne R. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature. 1986 Oct 23;323(6090):734–738. doi: 10.1038/323734a0. [DOI] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Lestavel-Delattre S., Martin-Nizard F., Clavey V., Testard P., Favre G., Doualin G., Houssaini H. S., Bard J. M., Duriez P., Delbart C. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 1992 Jul 1;52(13):3629–3635. [PubMed] [Google Scholar]
  20. Lombardi P., Norata G., Maggi F. M., Canti G., Franco P., Nicolin A., Catapano A. L. Assimilation of LDL by experimental tumours in mice. Biochim Biophys Acta. 1989 Jun 28;1003(3):301–306. doi: 10.1016/0005-2760(89)90236-1. [DOI] [PubMed] [Google Scholar]
  21. Mahley R. W., Weisgraber K. H., Melchior G. W., Innerarity T. L., Holcombe K. S. Inhibition of receptor-mediated clearance of lysine and arginine-modified lipoproteins from the plasma of rats and monkeys. Proc Natl Acad Sci U S A. 1980 Jan;77(1):225–229. doi: 10.1073/pnas.77.1.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Moerlein S. M., Dalal K. B., Ebbe S. N., Yano Y., Budinger T. F. Residualizing and non-residualizing analogues of low-density lipoprotein as iodine-123 radiopharmaceuticals for imaging LDL catabolism. Int J Rad Appl Instrum B. 1988;15(2):141–149. doi: 10.1016/0883-2897(88)90080-3. [DOI] [PubMed] [Google Scholar]
  23. Mosley S. T., Goldstein J. L., Brown M. S., Falck J. R., Anderson R. G. Targeted killing of cultured cells by receptor-dependent photosensitization. Proc Natl Acad Sci U S A. 1981 Sep;78(9):5717–5721. doi: 10.1073/pnas.78.9.5717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Norata G., Canti G., Ricci L., Nicolin A., Trezzi E., Catapano A. L. In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. Cancer Lett. 1984 Dec;25(2):203–208. doi: 10.1016/s0304-3835(84)80046-4. [DOI] [PubMed] [Google Scholar]
  25. Pittman R. C., Carew T. E., Glass C. K., Green S. R., Taylor C. A., Jr, Attie A. D. A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J. 1983 Jun 15;212(3):791–800. doi: 10.1042/bj2120791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ponty E., Favre G., Benaniba R., Boneu A., Lucot H., Carton M., Soula G. Biodistribution study of 99mTc-labeled LDL in B16-melanoma-bearing mice. Visualization of a preferential uptake by the tumor. Int J Cancer. 1993 May 28;54(3):411–417. doi: 10.1002/ijc.2910540311. [DOI] [PubMed] [Google Scholar]
  27. Redgrave T. G., Roberts D. C., West C. E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975 May 12;65(1-2):42–49. doi: 10.1016/0003-2697(75)90488-1. [DOI] [PubMed] [Google Scholar]
  28. Salter A. M., Bugaut M., Saxton J., Fisher S. C., Brindley D. N. Effects of preincubation of primary monolayer cultures of rat hepatocytes with low- and high-density lipoproteins on the subsequent binding and metabolism of human low-density lipoprotein. Biochem J. 1987 Oct 1;247(1):79–84. doi: 10.1042/bj2470079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Seglen P. O., Grinde B., Solheim A. E. Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. Eur J Biochem. 1979 Apr 2;95(2):215–225. doi: 10.1111/j.1432-1033.1979.tb12956.x. [DOI] [PubMed] [Google Scholar]
  30. Speth P. A., van Hoesel Q. G., Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988 Jul;15(1):15–31. doi: 10.2165/00003088-198815010-00002. [DOI] [PubMed] [Google Scholar]
  31. Trail P. A., Willner D., Lasch S. J., Henderson A. J., Hofstead S., Casazza A. M., Firestone R. A., Hellström I., Hellström K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993 Jul 9;261(5118):212–215. doi: 10.1126/science.8327892. [DOI] [PubMed] [Google Scholar]
  32. Vallabhajosula S., Paidi M., Badimon J. J., Le N. A., Goldsmith S. J., Fuster V., Ginsberg H. N. Radiotracers for low density lipoprotein biodistribution studies in vivo: technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. J Nucl Med. 1988 Jul;29(7):1237–1245. [PubMed] [Google Scholar]
  33. Van Berkel T. J., Kruijt J. K., Van Gent T., Van Tol A. Saturable high affinity binding, uptake and degradation of rat plasma lipoproteins by isolated parenchymal and non-parenchymal cells from rat liver. Biochim Biophys Acta. 1981 Jul 24;665(1):22–33. doi: 10.1016/0005-2760(81)90227-7. [DOI] [PubMed] [Google Scholar]
  34. Vitols S. G., Masquelier M., Peterson C. O. Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts. J Med Chem. 1985 Apr;28(4):451–454. doi: 10.1021/jm00382a011. [DOI] [PubMed] [Google Scholar]
  35. Weisgraber K. H., Innerarity T. L., Mahley R. W. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem. 1978 Dec 25;253(24):9053–9062. [PubMed] [Google Scholar]
  36. Weisgraber K. H., Mahley R. W. Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. J Lipid Res. 1980 Mar;21(3):316–325. [PubMed] [Google Scholar]
  37. van Dijk M. C., Ziere G. J., Boers W., Linthorst C., Bijsterbosch M. K., van Berkel T. J. Recognition of chylomicron remnants and beta-migrating very-low-density lipoproteins by the remnant receptor of parenchymal liver cells is distinct from the liver alpha 2-macroglobulin-recognition site. Biochem J. 1991 Nov 1;279(Pt 3):863–870. doi: 10.1042/bj2790863. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES